{
    "abstract": "Recombinant viral vaccines expressing antigens of pathogenic microbes (e.g., HIV, Ebola virus, and malaria) have been designed to overcome the insufficient immune responses induced by the conventional vaccines. Our knowledge of and clinical experience with the new recombinant viral vaccines are insufficient, and a clear regulatory pathway is needed for the further development and evaluation of recombinant viral vaccines. In 2018, the research group supported by the Ministry of Health, Labour and Welfare, Japan (MHLW) published a concept paper to address the development of recombinant viral vaccines against infectious diseases. Herein we summarize the concept paper\u2014which explains the Japanese regulatory concerns about recombinant viral vaccines\u2014and provide a focus of discussion about the development of recombinant viral vaccines.",
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Bahar",
                    "initial": "B.",
                    "last": "Ramezanpour"
                },
                {
                    "first": "Ingrid",
                    "initial": "I.",
                    "last": "Haan"
                },
                {
                    "first": "Ab",
                    "initial": "A.",
                    "last": "Osterhaus"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Claassen"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.06.059",
            "firstpage": "6436",
            "issn": "0264410X",
            "lastpage": "6448",
            "pmid": "28029542",
            "pub_year": 2016,
            "title": "Vector-based genetically modified vaccines: Exploiting Jenner's legacy",
            "volume": "34"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Ana Maria",
                    "initial": "A.M.",
                    "last": "Henao-Restrepo"
                },
                {
                    "first": "Anton",
                    "initial": "A.",
                    "last": "Camacho"
                },
                {
                    "first": "Ira M.",
                    "initial": "I.M.",
                    "last": "Longini"
                },
                {
                    "first": "Conall H.",
                    "initial": "C.H.",
                    "last": "Watson"
                },
                {
                    "first": "W. John",
                    "initial": "W.J.",
                    "last": "Edmunds"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "Egger"
                },
                {
                    "first": "Miles W.",
                    "initial": "M.W.",
                    "last": "Carroll"
                },
                {
                    "first": "Natalie E.",
                    "initial": "N.E.",
                    "last": "Dean"
                },
                {
                    "first": "Ibrahima",
                    "initial": "I.",
                    "last": "Diatta"
                },
                {
                    "first": "Moussa",
                    "initial": "M.",
                    "last": "Doumbia"
                },
                {
                    "first": "Bertrand",
                    "initial": "B.",
                    "last": "Draguez"
                },
                {
                    "first": "Sophie",
                    "initial": "S.",
                    "last": "Duraffour"
                },
                {
                    "first": "Godwin",
                    "initial": "G.",
                    "last": "Enwere"
                },
                {
                    "first": "Rebecca",
                    "initial": "R.",
                    "last": "Grais"
                },
                {
                    "first": "Stephan",
                    "initial": "S.",
                    "last": "Gunther"
                },
                {
                    "first": "Pierre St\u00e9phane",
                    "initial": "P.S.",
                    "last": "Gsell"
                },
                {
                    "first": "Stefanie",
                    "initial": "S.",
                    "last": "Hossmann"
                },
                {
                    "first": "Sara Viksmoen",
                    "initial": "S.V.",
                    "last": "Watle"
                },
                {
                    "first": "Mandy Kader",
                    "initial": "M.K.",
                    "last": "Kond\u00e9"
                },
                {
                    "first": "Sakoba",
                    "initial": "S.",
                    "last": "K\u00e9\u00efta"
                },
                {
                    "first": "Souleymane",
                    "initial": "S.",
                    "last": "Kone"
                },
                {
                    "first": "Eewa",
                    "initial": "E.",
                    "last": "Kuisma"
                },
                {
                    "first": "Myron M.",
                    "initial": "M.M.",
                    "last": "Levine"
                },
                {
                    "first": "Sema",
                    "initial": "S.",
                    "last": "Mandal"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Mauget"
                },
                {
                    "first": "Gunnstein",
                    "initial": "G.",
                    "last": "Norheim"
                },
                {
                    "first": "Ximena",
                    "initial": "X.",
                    "last": "Riveros"
                },
                {
                    "first": "Aboubacar",
                    "initial": "A.",
                    "last": "Soumah"
                },
                {
                    "first": "Sven",
                    "initial": "S.",
                    "last": "Trelle"
                },
                {
                    "first": "Andrea S.",
                    "initial": "A.S.",
                    "last": "Vicari"
                },
                {
                    "first": "John Arne",
                    "initial": "J.A.",
                    "last": "R\u00f8ttingen"
                },
                {
                    "first": "Marie Paule",
                    "initial": "M.P.",
                    "last": "Kieny"
                }
            ],
            "doi": "10.1016/S0140-6736(16)32621-6",
            "firstpage": "505",
            "issn": "01406736",
            "lastpage": "518",
            "pmid": "28017403",
            "pub_year": 2017,
            "title": "Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)",
            "volume": "389"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Bruno",
                    "initial": "B.",
                    "last": "Guy"
                },
                {
                    "first": "Beatrice",
                    "initial": "B.",
                    "last": "Barrere"
                },
                {
                    "first": "Claire",
                    "initial": "C.",
                    "last": "Malinowski"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Saville"
                },
                {
                    "first": "Remy",
                    "initial": "R.",
                    "last": "Teyssou"
                },
                {
                    "first": "Jean",
                    "initial": "J.",
                    "last": "Lang"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.06.094",
            "firstpage": "7229",
            "issn": "0264410X",
            "lastpage": "7241",
            "pmid": "21745521",
            "pub_year": 2011,
            "title": "From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine",
            "volume": "29"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Bruno",
                    "initial": "B.",
                    "last": "Guy"
                },
                {
                    "first": "Farshad",
                    "initial": "F.",
                    "last": "Guirakhoo"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Barban"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Higgs"
                },
                {
                    "first": "Thomas P.",
                    "initial": "T.P.",
                    "last": "Monath"
                },
                {
                    "first": "Jean",
                    "initial": "J.",
                    "last": "Lang"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.09.098",
            "firstpage": "632",
            "issn": "0264410X",
            "lastpage": "649",
            "pmid": "19808029",
            "pub_year": 2010,
            "title": "Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses",
            "volume": "28"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Robert T.",
                    "initial": "R.T.",
                    "last": "Chen"
                },
                {
                    "first": "Baevin",
                    "initial": "B.",
                    "last": "Carbery"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Mac"
                },
                {
                    "first": "Kenneth I.",
                    "initial": "K.I.",
                    "last": "Berns"
                },
                {
                    "first": "Louisa",
                    "initial": "L.",
                    "last": "Chapman"
                },
                {
                    "first": "Richard C.",
                    "initial": "R.C.",
                    "last": "Condit"
                },
                {
                    "first": "Jean Louis",
                    "initial": "J.L.",
                    "last": "Excler"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Gurwith"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Hendry"
                },
                {
                    "first": "Arifa S.",
                    "initial": "A.S.",
                    "last": "Khan"
                },
                {
                    "first": "Najwa",
                    "initial": "N.",
                    "last": "Khuri-Bulos"
                },
                {
                    "first": "Bettina",
                    "initial": "B.",
                    "last": "Klug"
                },
                {
                    "first": "James S.",
                    "initial": "J.S.",
                    "last": "Robertson"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Seligman"
                },
                {
                    "first": "Rebecca",
                    "initial": "R.",
                    "last": "Sheets"
                },
                {
                    "first": "Anna Lise",
                    "initial": "A.L.",
                    "last": "Williamson"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.09.035",
            "firstpage": "73",
            "issn": "0264410X",
            "lastpage": "75",
            "pmid": "25305565",
            "pub_year": 2015,
            "title": "The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)",
            "volume": "33"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Richard C.",
                    "initial": "R.C.",
                    "last": "Condit"
                },
                {
                    "first": "Anna Lise",
                    "initial": "A.L.",
                    "last": "Williamson"
                },
                {
                    "first": "Rebecca",
                    "initial": "R.",
                    "last": "Sheets"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Seligman"
                },
                {
                    "first": "Thomas P.",
                    "initial": "T.P.",
                    "last": "Monath"
                },
                {
                    "first": "Jean Louis",
                    "initial": "J.L.",
                    "last": "Excler"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Gurwith"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Bok"
                },
                {
                    "first": "James S.",
                    "initial": "J.S.",
                    "last": "Robertson"
                },
                {
                    "first": "Denny",
                    "initial": "D.",
                    "last": "Kim"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Michael Hendry"
                },
                {
                    "first": "Vidisha",
                    "initial": "V.",
                    "last": "Singh"
                },
                {
                    "first": "Lisa M.",
                    "initial": "L.M.",
                    "last": "Mac"
                },
                {
                    "first": "Robert T.",
                    "initial": "R.T.",
                    "last": "Chen"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.04.060",
            "firstpage": "6610",
            "issn": "0264410X",
            "lastpage": "6616",
            "pmid": "27346303",
            "pub_year": 2016,
            "title": "Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains",
            "volume": "34"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Sonali",
                    "initial": "S.",
                    "last": "Kochhar"
                },
                {
                    "first": "Jean Louis",
                    "initial": "J.L.",
                    "last": "Excler"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Bok"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Gurwith"
                },
                {
                    "first": "Michael M.",
                    "initial": "M.M.",
                    "last": "McNeil"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Seligman"
                },
                {
                    "first": "Najwa",
                    "initial": "N.",
                    "last": "Khuri-Bulos"
                },
                {
                    "first": "Bettina",
                    "initial": "B.",
                    "last": "Klug"
                },
                {
                    "first": "Marian",
                    "initial": "M.",
                    "last": "Laderoute"
                },
                {
                    "first": "James S.",
                    "initial": "J.S.",
                    "last": "Robertson"
                },
                {
                    "first": "Vidisha",
                    "initial": "V.",
                    "last": "Singh"
                },
                {
                    "first": "Robert T.",
                    "initial": "R.T.",
                    "last": "Chen"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2018.08.085",
            "firstpage": "5796",
            "issn": "0264410X",
            "lastpage": "5802",
            "pmid": "30497831",
            "pub_year": 2019,
            "title": "Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines",
            "volume": "37"
        },
        "b0040": null,
        "b0045": null,
        "b0050": null,
        "b0055": null,
        "b0060": {
            "authors": [
                {
                    "first": "Hugues",
                    "initial": "H.",
                    "last": "Fausther-Bovendo"
                },
                {
                    "first": "Gary P.",
                    "initial": "G.P.",
                    "last": "Kobinger"
                }
            ],
            "doi": "10.4161/hv.29594",
            "firstpage": "2875",
            "issn": "21645515",
            "lastpage": "2884",
            "pmid": "25483662",
            "pub_year": 2014,
            "title": "Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what's important?",
            "volume": "10"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Thomas P.",
                    "initial": "T.P.",
                    "last": "Monath"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Seligman"
                },
                {
                    "first": "James S.",
                    "initial": "J.S.",
                    "last": "Robertson"
                },
                {
                    "first": "Bruno",
                    "initial": "B.",
                    "last": "Guy"
                },
                {
                    "first": "Edward B.",
                    "initial": "E.B.",
                    "last": "Hayes"
                },
                {
                    "first": "Richard C.",
                    "initial": "R.C.",
                    "last": "Condit"
                },
                {
                    "first": "Jean Louis",
                    "initial": "J.L.",
                    "last": "Excler"
                },
                {
                    "first": "Lisa Marie",
                    "initial": "L.M.",
                    "last": "Mac"
                },
                {
                    "first": "Baevin",
                    "initial": "B.",
                    "last": "Carbery"
                },
                {
                    "first": "Robert T.",
                    "initial": "R.T.",
                    "last": "Chen"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.10.004",
            "firstpage": "62",
            "issn": "0264410X",
            "lastpage": "72",
            "pmid": "25446819",
            "pub_year": 2015,
            "title": "Live virus vaccines based on a yellow fever vaccine backbone: Standardized template with key considerations for a risk/benefit assessment",
            "volume": "33"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Mohan Babu",
                    "initial": "M.B.",
                    "last": "Appaiahgari"
                },
                {
                    "first": "Sudhanshu",
                    "initial": "S.",
                    "last": "Vrati"
                }
            ],
            "doi": "10.1586/erv.10.139",
            "firstpage": "1371",
            "issn": "14760584",
            "lastpage": "1384",
            "pmid": "21105774",
            "pub_year": 2010,
            "title": "IMOJEV\u00ae: A Yellow fever virus-based novel Japanese encephalitis vaccine",
            "volume": "9"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Maria Rosario",
                    "initial": "M.R.",
                    "last": "Capeding"
                },
                {
                    "first": "Ngoc Huu",
                    "initial": "N.H.",
                    "last": "Tran"
                },
                {
                    "first": "Sri Rezeki S.",
                    "initial": "S.R.S.",
                    "last": "Hadinegoro"
                },
                {
                    "first": "Hussain Imam Hj Muhammad",
                    "initial": "H.I.H.M.",
                    "last": "Ismail"
                },
                {
                    "first": "Tawee",
                    "initial": "T.",
                    "last": "Chotpitayasunondh"
                },
                {
                    "first": "Mary Noreen",
                    "initial": "M.N.",
                    "last": "Chua"
                },
                {
                    "first": "Chan Quang",
                    "initial": "C.Q.",
                    "last": "Luong"
                },
                {
                    "first": "Kusnandi",
                    "initial": "K.",
                    "last": "Rusmil"
                },
                {
                    "first": "Dewa Nyoman",
                    "initial": "D.N.",
                    "last": "Wirawan"
                },
                {
                    "first": "Revathy",
                    "initial": "R.",
                    "last": "Nallusamy"
                },
                {
                    "first": "Punnee",
                    "initial": "P.",
                    "last": "Pitisuttithum"
                },
                {
                    "first": "Usa",
                    "initial": "U.",
                    "last": "Thisyakorn"
                },
                {
                    "first": "In Kyu",
                    "initial": "I.K.",
                    "last": "Yoon"
                },
                {
                    "first": "Diane",
                    "initial": "D.",
                    "last": "Van Der Vliet"
                },
                {
                    "first": "Edith",
                    "initial": "E.",
                    "last": "Langevin"
                },
                {
                    "first": "Thelma",
                    "initial": "T.",
                    "last": "Laot"
                },
                {
                    "first": "Yanee",
                    "initial": "Y.",
                    "last": "Hutagalung"
                },
                {
                    "first": "Carina",
                    "initial": "C.",
                    "last": "Frago"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Boaz"
                },
                {
                    "first": "T. Anh",
                    "initial": "T.A.",
                    "last": "Wartel"
                },
                {
                    "first": "Nadia G.",
                    "initial": "N.G.",
                    "last": "Tornieporth"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Saville"
                },
                {
                    "first": "Alain",
                    "initial": "A.",
                    "last": "Bouckenooghe"
                }
            ],
            "doi": "10.1016/S0140-6736(14)61060-6",
            "firstpage": "1358",
            "issn": "01406736",
            "lastpage": "1365",
            "pmid": "25018116",
            "pub_year": 2014,
            "title": "Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial",
            "volume": "384"
        },
        "b0080": {
            "authors": [
                {
                    "first": "David K.",
                    "initial": "D.K.",
                    "last": "Clarke"
                },
                {
                    "first": "R. Michael",
                    "initial": "R.M.",
                    "last": "Hendry"
                },
                {
                    "first": "Vidisha",
                    "initial": "V.",
                    "last": "Singh"
                },
                {
                    "first": "John K.",
                    "initial": "J.K.",
                    "last": "Rose"
                },
                {
                    "first": "Stephen J.",
                    "initial": "S.J.",
                    "last": "Seligman"
                },
                {
                    "first": "Bettina",
                    "initial": "B.",
                    "last": "Klug"
                },
                {
                    "first": "Sonali",
                    "initial": "S.",
                    "last": "Kochhar"
                },
                {
                    "first": "Lisa Marie",
                    "initial": "L.M.",
                    "last": "Mac"
                },
                {
                    "first": "Baevin",
                    "initial": "B.",
                    "last": "Carbery"
                },
                {
                    "first": "Robert T.",
                    "initial": "R.T.",
                    "last": "Chen"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.06.071",
            "firstpage": "6597",
            "issn": "0264410X",
            "lastpage": "6609",
            "pmid": "27395563",
            "pub_year": 2016,
            "title": "Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment",
            "volume": "34"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Pierre St\u00e9phane",
                    "initial": "P.S.",
                    "last": "Gsell"
                },
                {
                    "first": "Anton",
                    "initial": "A.",
                    "last": "Camacho"
                },
                {
                    "first": "Adam J.",
                    "initial": "A.J.",
                    "last": "Kucharski"
                },
                {
                    "first": "Conall H.",
                    "initial": "C.H.",
                    "last": "Watson"
                },
                {
                    "first": "Aminata",
                    "initial": "A.",
                    "last": "Bagayoko"
                },
                {
                    "first": "S\u00e9verine Danmadji",
                    "initial": "S.D.",
                    "last": "Nadlaou"
                },
                {
                    "first": "Natalie E.",
                    "initial": "N.E.",
                    "last": "Dean"
                },
                {
                    "first": "Abdourahamane",
                    "initial": "A.",
                    "last": "Diallo"
                },
                {
                    "first": "Abdourahmane",
                    "initial": "A.",
                    "last": "Diallo"
                },
                {
                    "first": "Djidonou A.",
                    "initial": "D.A.",
                    "last": "Honora"
                },
                {
                    "first": "Moussa",
                    "initial": "M.",
                    "last": "Doumbia"
                },
                {
                    "first": "Godwin",
                    "initial": "G.",
                    "last": "Enwere"
                },
                {
                    "first": "Elizabeth S.",
                    "initial": "E.S.",
                    "last": "Higgs"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Mauget"
                },
                {
                    "first": "Diakite",
                    "initial": "D.",
                    "last": "Mory"
                },
                {
                    "first": "Ximena",
                    "initial": "X.",
                    "last": "Riveros"
                },
                {
                    "first": "Fofana Thierno",
                    "initial": "F.T.",
                    "last": "Oumar"
                },
                {
                    "first": "Mosoka",
                    "initial": "M.",
                    "last": "Fallah"
                },
                {
                    "first": "Alhassane",
                    "initial": "A.",
                    "last": "Toure"
                },
                {
                    "first": "Andrea S.",
                    "initial": "A.S.",
                    "last": "Vicari"
                },
                {
                    "first": "Ira M.",
                    "initial": "I.M.",
                    "last": "Longini"
                },
                {
                    "first": "W. J.",
                    "initial": "W.J.",
                    "last": "Edmunds"
                },
                {
                    "first": "Ana Maria",
                    "initial": "A.M.",
                    "last": "Henao-Restrepo"
                },
                {
                    "first": "Marie Paule",
                    "initial": "M.P.",
                    "last": "Kieny"
                },
                {
                    "first": "Sakoba",
                    "initial": "S.",
                    "last": "K\u00e9\u00efta"
                }
            ],
            "doi": "10.1016/S1473-3099(17)30541-8",
            "firstpage": "1276",
            "issn": "14733099",
            "lastpage": "1284",
            "pmid": "29033032",
            "pub_year": 2017,
            "title": "Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report",
            "volume": "17"
        },
        "b0090": {
            "authors": [
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Regules"
                },
                {
                    "first": "J. H.",
                    "initial": "J.H.",
                    "last": "Beigel"
                },
                {
                    "first": "K. M.",
                    "initial": "K.M.",
                    "last": "Paolino"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Voell"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Castellano"
                },
                {
                    "first": "Z.",
                    "initial": "Z.",
                    "last": "Hu"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Mu\u00f1oz"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "Moon"
                },
                {
                    "first": "R. C.",
                    "initial": "R.C.",
                    "last": "Ruck"
                },
                {
                    "first": "J. W.",
                    "initial": "J.W.",
                    "last": "Bennett"
                },
                {
                    "first": "P. S.",
                    "initial": "P.S.",
                    "last": "Twomey"
                },
                {
                    "first": "R. L.",
                    "initial": "R.L.",
                    "last": "Guti\u00e9rrez"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "Remich"
                },
                {
                    "first": "H. R.",
                    "initial": "H.R.",
                    "last": "Hack"
                },
                {
                    "first": "M. L.",
                    "initial": "M.L.",
                    "last": "Wisniewski"
                },
                {
                    "first": "M. D.",
                    "initial": "M.D.",
                    "last": "Josleyn"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "Kwilas"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Van Deusen"
                },
                {
                    "first": "O. T.",
                    "initial": "O.T.",
                    "last": "Mbaya"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Zhou"
                },
                {
                    "first": "D. A.",
                    "initial": "D.A.",
                    "last": "Stanley"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Jing"
                },
                {
                    "first": "K. S.",
                    "initial": "K.S.",
                    "last": "Smith"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Shi"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "Ledgerwood"
                },
                {
                    "first": "B. S.",
                    "initial": "B.S.",
                    "last": "Graham"
                },
                {
                    "first": "N. J.",
                    "initial": "N.J.",
                    "last": "Sullivan"
                },
                {
                    "first": "L. L.",
                    "initial": "L.L.",
                    "last": "Jagodzinski"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "Peel"
                },
                {
                    "first": "J. B.",
                    "initial": "J.B.",
                    "last": "Alimonti"
                },
                {
                    "first": "J. W.",
                    "initial": "J.W.",
                    "last": "Hooper"
                },
                {
                    "first": "P. M.",
                    "initial": "P.M.",
                    "last": "Silvera"
                },
                {
                    "first": "B. K.",
                    "initial": "B.K.",
                    "last": "Martin"
                },
                {
                    "first": "T. P.",
                    "initial": "T.P.",
                    "last": "Monath"
                },
                {
                    "first": "W. J.",
                    "initial": "W.J.",
                    "last": "Ramsey"
                },
                {
                    "first": "C. J.",
                    "initial": "C.J.",
                    "last": "Link"
                },
                {
                    "first": "H. C.",
                    "initial": "H.C.",
                    "last": "Lane"
                },
                {
                    "first": "N. L.",
                    "initial": "N.L.",
                    "last": "Michael"
                },
                {
                    "first": "R. T.",
                    "initial": "R.T.",
                    "last": "Davey"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Thomas"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1056/NEJMoa1414216",
            "firstpage": "330",
            "issn": "00284793",
            "lastpage": "341",
            "pmid": "25830322",
            "pub_year": 2017,
            "title": "A Recombinant Vesicular Stomatitis Virus Ebola Vaccine",
            "volume": "376"
        },
        "b0095": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Volz"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Sutter"
                }
            ],
            "doi": "10.1016/bs.aivir.2016.07.001",
            "firstpage": "187",
            "issn": "00653527",
            "lastpage": "243",
            "pmid": "28057259",
            "pub_year": 2017,
            "title": "Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development",
            "volume": "97"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Lindvi",
                    "initial": "L.",
                    "last": "Gudmundsdotter"
                },
                {
                    "first": "Charlotta",
                    "initial": "C.",
                    "last": "Nilsson"
                },
                {
                    "first": "Andreas",
                    "initial": "A.",
                    "last": "Brave"
                },
                {
                    "first": "Bo",
                    "initial": "B.",
                    "last": "Hejdeman"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Earl"
                },
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Moss"
                },
                {
                    "first": "Merlin",
                    "initial": "M.",
                    "last": "Robb"
                },
                {
                    "first": "Josephine",
                    "initial": "J.",
                    "last": "Cox"
                },
                {
                    "first": "Nelson",
                    "initial": "N.",
                    "last": "Michael"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Marovich"
                },
                {
                    "first": "Gunnel",
                    "initial": "G.",
                    "last": "Biberfeld"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Sandstr\u00f6m"
                },
                {
                    "first": "Britta",
                    "initial": "B.",
                    "last": "Wahren"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.05.018",
            "firstpage": "4468",
            "issn": "0264410X",
            "lastpage": "4474",
            "pmid": "19450644",
            "pub_year": 2009,
            "title": "Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity",
            "volume": "27"
        },
        "b0105": null,
        "b0110": null,
        "b0115": {
            "authors": [
                {
                    "first": "Lauren R.",
                    "initial": "L.R.",
                    "last": "Platt"
                },
                {
                    "first": "Concepcion F.",
                    "initial": "C.F.",
                    "last": "Estivariz"
                },
                {
                    "first": "Roland W.",
                    "initial": "R.W.",
                    "last": "Sutter"
                }
            ],
            "doi": "10.1093/infdis/jiu184",
            "firstpage": "S380",
            "issn": "00221899",
            "lastpage": "S389",
            "pmid": "25316859",
            "pub_year": 2014,
            "title": "Vaccine-associated paralytic poliomyelitis: A review of the epidemiology and estimation of the global burden",
            "volume": "210"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Mike",
                    "initial": "M.",
                    "last": "Bray"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Wright"
                }
            ],
            "doi": "10.1086/374244",
            "firstpage": "766",
            "issn": "10584838",
            "lastpage": "774",
            "pmid": "12627361",
            "pub_year": 2003,
            "title": "Progressive vaccinia",
            "volume": "36"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Robert E.",
                    "initial": "R.E.",
                    "last": "Eckart"
                },
                {
                    "first": "Suzanne S.",
                    "initial": "S.S.",
                    "last": "Love"
                },
                {
                    "first": "J. Edwin",
                    "initial": "J.E.",
                    "last": "Atwood"
                },
                {
                    "first": "Mark K.",
                    "initial": "M.K.",
                    "last": "Arness"
                },
                {
                    "first": "Dimitri C.",
                    "initial": "D.C.",
                    "last": "Cassimatis"
                },
                {
                    "first": "Charles L.",
                    "initial": "C.L.",
                    "last": "Campbell"
                },
                {
                    "first": "Sheri Y.",
                    "initial": "S.Y.",
                    "last": "Boyd"
                },
                {
                    "first": "Joseph G.",
                    "initial": "J.G.",
                    "last": "Murphy"
                },
                {
                    "first": "David L.",
                    "initial": "D.L.",
                    "last": "Swerdlow"
                },
                {
                    "first": "Limone C.",
                    "initial": "L.C.",
                    "last": "Collins"
                },
                {
                    "first": "James R.",
                    "initial": "J.R.",
                    "last": "Riddle"
                },
                {
                    "first": "David N.",
                    "initial": "D.N.",
                    "last": "Tornberg"
                },
                {
                    "first": "John D.",
                    "initial": "J.D.",
                    "last": "Grabenstein"
                },
                {
                    "first": "Renata J.M.",
                    "initial": "R.J.M.",
                    "last": "Engler"
                }
            ],
            "doi": "10.1016/j.jacc.2004.05.004",
            "firstpage": "201",
            "issn": "07351097",
            "lastpage": "205",
            "pub_year": 2004,
            "title": "Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination",
            "volume": "44"
        }
    },
    "body_text": [
        {
            "endOffset": 12533,
            "parents": [],
            "secId": "s0005",
            "sentence": "These vaccines are produced as a recombinant virus and are intended to prevent infection with a virus or pathogen through the expression of target antigen(s) as the active ingredient (hereinafter referred to as \u201crecombinant viral vaccines\u201d).",
            "startOffset": 12292,
            "title": "Introduction"
        },
        {
            "endOffset": 28819,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0095",
            "sentence": "Recombinant viral vaccines, which not only retain the ability to express the transgene(s) and present antigens in the human body, but also the ability to be shed from the vaccine recipient, may be transmitted to persons in close contact with the recipient and induce undesirable events in these individuals.",
            "startOffset": 28512,
            "title": "Principles of the evaluation of shedding and transmission to third parties"
        },
        {
            "endOffset": 30623,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0105",
            "sentence": "If necessary, measures to mitigate the risk should be conducted.",
            "startOffset": 30559,
            "title": "Principles of safety evaluations"
        },
        {
            "endOffset": 33448,
            "parents": [],
            "secId": "s0125",
            "sentence": "Nevertheless, there are several concerns about these new vaccines (Table 3), including their pathogenicity to immunocompromised individuals, potential spread to third parties, recombination with wild-type viruses, and reversion of virulence.",
            "startOffset": 33207,
            "title": "Conclusion"
        },
        {
            "endOffset": 14113,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 14112,
                    "startOffset": 14107
                },
                "b0030": {
                    "endOffset": 14112,
                    "startOffset": 14107
                },
                "b0035": {
                    "endOffset": 14112,
                    "startOffset": 14107
                }
            },
            "secId": "s0005",
            "sentence": "Replication-competent recombinant viral vaccines in particular pose a risk for not only immunocompromised individuals but also third parties through the viral shedding from the vaccinated individuals, and additional safety risks due to viral shedding should thus be carefully evaluated [5\u20137].",
            "startOffset": 13821,
            "title": "Introduction"
        },
        {
            "endOffset": 18369,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0020",
            "sentence": "There are no approved replication-incompetent viral vaccines available in Japan or other countries at present.",
            "startOffset": 18259,
            "title": "Replication-incompetent viral vaccines"
        },
        {
            "endOffset": 19946,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "refoffsets": {
                "b0080": {
                    "endOffset": 19945,
                    "startOffset": 19941
                }
            },
            "secId": "s0025",
            "sentence": "Vaccines based on a vesicular stomatitis virus (VSV) backbone are also in advanced clinical trials [16].",
            "startOffset": 19842,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 23483,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0045",
            "sentence": "The genetic stability of the recombinant virus (mutation, reversion to virulence, and alteration of replication-competence) during the manufacturing process should also be assessed.",
            "startOffset": 23302,
            "title": "Evaluation during the manufacturing process"
        },
        {
            "endOffset": 30938,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0105",
            "sentence": "The risk of accidental recombination with other pathogenic viruses in the recipient\u2019s body, and the possibility of adverse events caused by recombination variants.",
            "startOffset": 30775,
            "title": "Principles of safety evaluations"
        },
        {
            "endOffset": 26457,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0070",
            "sentence": "In principle, the shedding of a recombinant virus should be evaluated.",
            "startOffset": 26387,
            "title": "Evaluations of the shedding of a recombinant virus"
        },
        {
            "endOffset": 18897,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0025",
            "sentence": "The design and construction of replication-competent viral vaccines are conducted mainly by two types of methods: the replacement of genes by a reverse genetics system, and the insertion of additional genes to a viral whole genome.",
            "startOffset": 18666,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 23025,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0040",
            "sentence": "Evaluation of process-related impurities specific to recombinant viruses; i.e., unexpected recombinant virus(es), residual plasmids, or helper virus(es).",
            "startOffset": 22872,
            "title": "Characterization of recombinant viruses"
        },
        {
            "endOffset": 13067,
            "parents": [],
            "secId": "s0005",
            "sentence": "This strategy is expected to induce a stronger immune response than the response induced by conventional vaccines because it elicits immunity via a mechanism of action similar to that of viral infection, and thus provides a continuous stimulation of both humoral and cellular immune reactions.",
            "startOffset": 12774,
            "title": "Introduction"
        },
        {
            "endOffset": 19462,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0025",
            "sentence": "Imojev\u00ae is licensed in Australia, Thailand and other Asian countries, but not in Japan, the U.S. or the EU.",
            "startOffset": 19355,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 27683,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0080",
            "sentence": "If a recombinant viral vaccine is based on an approved live attenuated vaccine, the two vaccines\u2019 mutual interference in immunogenicity should be evaluated by conducting non-clinical studies in which the recombinant viral vaccine is administered after the administration of the approved live vaccine, or vice versa.",
            "startOffset": 27368,
            "title": "Evaluations of immunogenicity"
        },
        {
            "endOffset": 19354,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "refoffsets": {
                "b0070": {
                    "endOffset": 19353,
                    "startOffset": 19349
                }
            },
            "secId": "s0025",
            "sentence": "The vaccine Imojev\u00ae is constructed from the genes that encode the prM and E proteins of Japanese encephalitis virus and other genes of the live attenuated yellow fever virus (YFV) vaccine [14].",
            "startOffset": 19161,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 26334,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                },
                {
                    "id": "s0060",
                    "title": "Biodistribution study"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 26333,
                    "startOffset": 26329
                }
            },
            "secId": "s0065",
            "sentence": "If a biodistribution study reveals that a recombinant virus is present in gonadal tissues, evaluations should then be conducted referencing the \u201cGeneral Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors\u201d issued by ICH [21].",
            "startOffset": 26070,
            "title": "Evaluations of the risk of germline integration"
        },
        {
            "endOffset": 23889,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 23888,
                    "startOffset": 23884
                }
            },
            "secId": "s0050",
            "sentence": "Non-clinical evaluations of recombinant viral vaccines should follow the Guideline for non-clinical studies of preventive vaccines for infectious diseases notified by MHLW [10].",
            "startOffset": 23712,
            "title": "Non-clinical studies of recombinant viral vaccines"
        },
        {
            "endOffset": 13412,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 13411,
                    "startOffset": 13406
                },
                "b0020": {
                    "endOffset": 13411,
                    "startOffset": 13406
                }
            },
            "secId": "s0005",
            "sentence": "Several countries have approved recombinant viral vaccines targeting viruses such as Japanese encephalitis virus and dengue virus [3,4].",
            "startOffset": 13276,
            "title": "Introduction"
        },
        {
            "endOffset": 19020,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0025",
            "sentence": "A reverse genetics system is used to synthesize molecular clones of live viruses by using cloned cDNA of the viral genome.",
            "startOffset": 18898,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 29675,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0095",
            "sentence": "Information on the persistence of a recombinant virus in the human body and its shedding duration will contribute to the design of rational measures to avoid transmission from recipients to third parties that can be applied to subsequent clinical studies.",
            "startOffset": 29420,
            "title": "Principles of the evaluation of shedding and transmission to third parties"
        },
        {
            "endOffset": 16389,
            "parents": [],
            "secId": "s0010",
            "sentence": "The concept paper does not cover a recombinant virus with a gene constitution equivalent to that seen in natural viruses, although these vaccines are manufactured using the genetic recombination technique.",
            "startOffset": 16184,
            "title": "Objectives and scope"
        },
        {
            "endOffset": 30352,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0100",
            "sentence": "The duration of contraception for women of childbearing potential should be set taking into account the non-clinical study data in addition to data on the persistence of the recombinant virus in human blood and the duration of shedding in body fluids.",
            "startOffset": 30101,
            "title": "Principles of the duration of contraception"
        },
        {
            "endOffset": 35074,
            "parents": [],
            "secId": "s0130",
            "sentence": "This review was supported by a grant-aid from the Ministry of Health, Labour and Welfare, Japan.",
            "startOffset": 34978,
            "title": "Funding"
        },
        {
            "endOffset": 14383,
            "parents": [],
            "secId": "s0005",
            "sentence": "In this context, when the development of recombinant viral vaccines is being considered, there is a need for quality, non-clinical, and clinical evaluations and safety measures conducted from a standpoint that differs from that used for conventional vaccines (Table 1).",
            "startOffset": 14114,
            "title": "Introduction"
        },
        {
            "endOffset": 31339,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 31338,
                    "startOffset": 31334
                }
            },
            "secId": "s0110",
            "sentence": "An efficacy evaluation of a recombinant viral vaccine should follow the Guideline for clinical studies of preventive vaccines for infectious diseases notified by MHLW [11].",
            "startOffset": 31167,
            "title": "Efficacy of recombinant viral vaccines"
        },
        {
            "endOffset": 24757,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0055",
            "sentence": "However, since recombinant viruses should be handled in a P2-level containment laboratory, some studies employing specialized test systems may not be able to comply fully with GLP.",
            "startOffset": 24577,
            "title": "Selection of animal species/models"
        },
        {
            "endOffset": 20716,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 20715,
                    "startOffset": 20711
                }
            },
            "secId": "s0025",
            "sentence": "There are several candidates for vaccinia-based and poxvirus-based chimeric vaccines, but no licensed poxvirus-based chimeric vaccines exist [20].",
            "startOffset": 20570,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 16478,
            "parents": [],
            "secId": "s0010",
            "sentence": "Nevertheless, some of the principles described herein could be applied to such vaccines.",
            "startOffset": 16390,
            "title": "Objectives and scope"
        },
        {
            "endOffset": 28084,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0085",
            "sentence": "To test this possibility, the necessity of conducting a vaccination study in immunocompromised animals should be considered.",
            "startOffset": 27960,
            "title": "Vaccination studies in immunocompromised animals"
        },
        {
            "endOffset": 19161,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "refoffsets": {
                "b0065": {
                    "endOffset": 19160,
                    "startOffset": 19156
                }
            },
            "secId": "s0025",
            "sentence": "Vaccines based on a flavivirus backbone are one of the most well-developed chimeric vaccines manufactured by a reverse genetics system [13].",
            "startOffset": 19021,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 24480,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0055",
            "sentence": "If no relevant animal models are available, animal models in which the recombinant virus expresses its antigens can be selected.",
            "startOffset": 24352,
            "title": "Selection of animal species/models"
        },
        {
            "endOffset": 20870,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0025",
            "sentence": "There are some licensed replication-competent viral vaccines that are thought to present a potential risk to immunocompromised vaccinee and third parties.",
            "startOffset": 20716,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 24063,
            "parents": [],
            "secId": "s0050",
            "sentence": "A biodistribution study and a shedding study should be performed, and their results should be taken into account to the recombinant viral vaccine\u2019s specific characteristics.",
            "startOffset": 23890,
            "title": "Non-clinical studies of recombinant viral vaccines"
        },
        {
            "endOffset": 25582,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "This leads to the identification of tissues and cells that should be focused on in the safety assessment and as part of the unintended integration risk in humans, and biodistribution results may thus be useful when considering the toxicological significance of tissue-specific abnormal findings detected in toxicity studies.",
            "startOffset": 25258,
            "title": "Biodistribution study"
        },
        {
            "endOffset": 31565,
            "parents": [
                {
                    "id": "s0110",
                    "title": "Efficacy of recombinant viral vaccines"
                }
            ],
            "secId": "s0115",
            "sentence": "The adequate efficacy of a recombinant viral vaccine is tested in one or more clinical studies that evaluate the disease-protective effect or anti-infective effect as the efficacy endpoint.",
            "startOffset": 31376,
            "title": "Principles of efficacy evaluations"
        },
        {
            "endOffset": 24351,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0055",
            "sentence": "Animal models capable of mimicking human infectious diseases should be used to prove the potency of the recombinant viral vaccine to prevent symptomatic disease prior to tests involving humans.",
            "startOffset": 24158,
            "title": "Selection of animal species/models"
        },
        {
            "endOffset": 16183,
            "parents": [],
            "secId": "s0010",
            "sentence": "The scope does not apply to inactivated recombinant viral vaccines, recombinant protein vaccines, or synthetic vaccines such as DNA vaccines or mRNA vaccines.",
            "startOffset": 16025,
            "title": "Objectives and scope"
        },
        {
            "endOffset": 19665,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "refoffsets": {
                "b0075": {
                    "endOffset": 19664,
                    "startOffset": 19660
                }
            },
            "secId": "s0025",
            "sentence": "Dengvaxia\u00ae, which is constructed by replacing the genes encoding the prM and E proteins of the attenuated live YFV vaccine with those of four types of dengue viruses, expresses four virus antigens [15].",
            "startOffset": 19463,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 28285,
            "parents": [],
            "secId": "s0090",
            "sentence": "Viral shedding and the potential transmission of the recombinant viruses to third parties should be assessed in at least a phase I clinical trial.",
            "startOffset": 28139,
            "title": "Viral shedding study and transmission to third parties"
        },
        {
            "endOffset": 19841,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0025",
            "sentence": "Dengvaxia\u00ae is licensed in the EU and US for adults, young people and children (from 9 to 45 years of age) who had a prior dengue virus infection and who live in endemic areas.",
            "startOffset": 19666,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 25117,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "To obtain basic data about the characteristics of a recombinant virus and its safety and efficacy, the biodistribution of the virus should be determined before a phase I trial is initiated, in principle.",
            "startOffset": 24914,
            "title": "Biodistribution study"
        },
        {
            "endOffset": 29012,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0095",
            "sentence": "Replication-competent recombinant viral vaccines in particular present a higher risk by transmission to particular populations such as newborns, pregnant women, and immunocompromised patients.",
            "startOffset": 28820,
            "title": "Principles of the evaluation of shedding and transmission to third parties"
        },
        {
            "endOffset": 29107,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0095",
            "sentence": "These vaccines should therefore be carefully evaluated for viral shedding in clinical studies.",
            "startOffset": 29013,
            "title": "Principles of the evaluation of shedding and transmission to third parties"
        },
        {
            "endOffset": 34217,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 34158,
                    "startOffset": 34154
                },
                "b0125": {
                    "endOffset": 34183,
                    "startOffset": 34179
                }
            },
            "secId": "s0125",
            "sentence": "In addition, attenuated vaccinia virus, which is one of the major original viruses of recombinant viral vaccines, was reported to present a risk of serious or fatal side effects such as \u2018progressive vaccinia\u2019 [24] and myopericarditis [25] in immunocompromised individuals.",
            "startOffset": 33945,
            "title": "Conclusion"
        },
        {
            "endOffset": 30100,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0100",
            "sentence": "The selection of the appropriate duration of male contraception in clinical studies should take into account the results of a biodistribution study and a shedding study of the recombinant virus.",
            "startOffset": 29906,
            "title": "Principles of the duration of contraception"
        },
        {
            "endOffset": 34971,
            "parents": [],
            "secId": "s0125",
            "sentence": "Basic and clinical research groups, vaccine developers, academics, and regulatory bodies should continue discussions of the benefits and risks of recombinant viral vaccines, and the development and regulation of recombinant viral vaccines should be based on a foundation of the latest scientific knowledge.",
            "startOffset": 34665,
            "title": "Conclusion"
        },
        {
            "endOffset": 22406,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0040",
            "sentence": "The following characterization of recombinant viruses should be performed.",
            "startOffset": 22332,
            "title": "Characterization of recombinant viruses"
        },
        {
            "endOffset": 24576,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0055",
            "sentence": "Toxicity studies are expected to be performed in compliance with Good Laboratory Practice (GLP).",
            "startOffset": 24480,
            "title": "Selection of animal species/models"
        },
        {
            "endOffset": 15389,
            "parents": [],
            "secId": "s0005",
            "sentence": "This review focuses on RVVRG\u2019s concept paper and discusses the current regulatory requirements in Japan for recombinant viral vaccines.",
            "startOffset": 15254,
            "title": "Introduction"
        },
        {
            "endOffset": 25257,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "A biodistribution analysis can establish the distribution not only in the expected tissues but also in non-expected tissues and germ cells.",
            "startOffset": 25118,
            "title": "Biodistribution study"
        },
        {
            "endOffset": 15689,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 15597,
                    "startOffset": 15593
                },
                "b0055": {
                    "endOffset": 15688,
                    "startOffset": 15684
                }
            },
            "secId": "s0010",
            "sentence": "The concept paper has been edited aimed to complement existing guidelines notified by MHLW, i.e., the Guideline for nonclinical studies of preventive vaccines for infectious diseases [10] and the Guideline for clinical studies of preventive vaccines for infectious diseases [11].",
            "startOffset": 15410,
            "title": "Objectives and scope"
        },
        {
            "endOffset": 34577,
            "parents": [],
            "secId": "s0125",
            "sentence": "The current knowledge about these vaccines indicates that recombinant viral vaccines could provide insight into the prevention of diseases caused by viruses that cannot be prevented by conventional vaccines.",
            "startOffset": 34370,
            "title": "Conclusion"
        },
        {
            "endOffset": 12773,
            "parents": [],
            "secId": "s0005",
            "sentence": "When such a vaccine is administered, the recombinant virus carrying the gene(s)\u2019 coding antigen(s)\u2014rather than injected proteins, virus-like particles (VLPs) or whole virions\u2014may serve as an antigen as in the case of conventional vaccines.",
            "startOffset": 12534,
            "title": "Introduction"
        },
        {
            "endOffset": 32624,
            "parents": [],
            "secId": "s0125",
            "sentence": "The research into and development of recombinant viral vaccines have been conducted in many laboratories as basic research, but there is as yet no accumulation of clinical experiences with these vaccines.",
            "startOffset": 32420,
            "title": "Conclusion"
        },
        {
            "endOffset": 23301,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0045",
            "sentence": "Drug products should be evaluated for its infectivity titer per virion (or the amount of protein or the viral genome copy), which is a useful parameter for evaluations of the consistency of the production of the recombinant virus.",
            "startOffset": 23071,
            "title": "Evaluation during the manufacturing process"
        },
        {
            "endOffset": 17285,
            "parents": [],
            "secId": "s0015",
            "sentence": "Some recombinant viral vaccines that are under development replicate under specific artificial or limited conditions, and these vaccines are not characterized into the above-mentioned two types of vaccines.",
            "startOffset": 17079,
            "title": "Current status of recombinant viral vaccines"
        },
        {
            "endOffset": 31948,
            "parents": [
                {
                    "id": "s0110",
                    "title": "Efficacy of recombinant viral vaccines"
                }
            ],
            "secId": "s0120",
            "sentence": "Humoral and cellular immune responses elicited by recombinant viral vaccines should be investigated at the early stage of clinical development whenever possible.",
            "startOffset": 31787,
            "title": "Principles of immunogenicity evaluations"
        },
        {
            "endOffset": 24121,
            "parents": [],
            "secId": "s0050",
            "sentence": "The EMA guideline also requires these additional studies.",
            "startOffset": 24064,
            "title": "Non-clinical studies of recombinant viral vaccines"
        },
        {
            "endOffset": 27959,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0085",
            "sentence": "Although a replication-competent recombinant viral vaccine may not have any pathogenicity in healthy individuals, it could induce serious events in individuals such as newborns, pregnant women, and immunocompromised patients.",
            "startOffset": 27734,
            "title": "Vaccination studies in immunocompromised animals"
        },
        {
            "endOffset": 22815,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "refoffsets": {
                "b0030": {
                    "endOffset": 22814,
                    "startOffset": 22811
                }
            },
            "secId": "s0040",
            "sentence": "Investigation of the risk of recombination/reassortment with wild-type viruses [6].",
            "startOffset": 22732,
            "title": "Characterization of recombinant viruses"
        },
        {
            "endOffset": 32126,
            "parents": [
                {
                    "id": "s0110",
                    "title": "Efficacy of recombinant viral vaccines"
                }
            ],
            "secId": "s0120",
            "sentence": "The non-clinical study data and previously available information about the relevant original non-recombinant virus will be helpful in deciding the extent of such investigations.",
            "startOffset": 31949,
            "title": "Principles of immunogenicity evaluations"
        },
        {
            "endOffset": 21657,
            "parents": [],
            "secId": "s0030",
            "sentence": "There are no major differences between RVVRG\u2019s concept paper and the EMA guideline regarding the quality evaluation requirements.",
            "startOffset": 21528,
            "title": "Quality aspects of recombinant viral vaccines and their characterization"
        },
        {
            "endOffset": 16865,
            "parents": [],
            "secId": "s0015",
            "sentence": "Recombinant viral vaccines can be categorized as mainly two types based on their replication ability: replication-incompetent viral vaccines that express the antigen of interest in infected cells (such as gene therapy vectors), and replication-competent viral vaccines that express the antigen (such as chimeric live viral vaccines) (Fig. 1).",
            "startOffset": 16523,
            "title": "Current status of recombinant viral vaccines"
        },
        {
            "endOffset": 17078,
            "parents": [],
            "secId": "s0015",
            "sentence": "There are major safety concerns regarding the replication competency of recombinant viruses and the pathogenicity of host viruses, because proliferated recombinant viruses in vaccinee might cause adverse effects.",
            "startOffset": 16866,
            "title": "Current status of recombinant viral vaccines"
        },
        {
            "endOffset": 18627,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0020",
            "sentence": "Replication-incompetent viral vaccines based on adenoviral vectors have demonstrated immunogenicity and protective immunity in animal models.",
            "startOffset": 18486,
            "title": "Replication-incompetent viral vaccines"
        },
        {
            "endOffset": 12155,
            "parents": [],
            "secId": "s0005",
            "sentence": "The new biotechnology and recombination techniques such as the reverse genetics method enable the rapid construction of recombinant viruses and provide an efficient manufacturing system.",
            "startOffset": 11969,
            "title": "Introduction"
        },
        {
            "endOffset": 14865,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 14594,
                    "startOffset": 14591
                }
            },
            "secId": "s0005",
            "sentence": "In 2009, the European Medicines Agency (EMA) issued a \u201cGuideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines\u201d (hereafter referred to as the \u20182009 EMA guideline\u2019) [8] which emphasizes safety issues such as the characterization of recombinant viruses, the occurrence of virulent revertant or recombined virus with wild-type viruses, clinical follow-up in healthy patients, and the possibility of integration into a chromosome or germline.",
            "startOffset": 14383,
            "title": "Introduction"
        },
        {
            "endOffset": 18485,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 18484,
                    "startOffset": 18480
                }
            },
            "secId": "s0020",
            "sentence": "Replication-defective adenovirus vectors are one of the candidates for replication-incompetent viral vaccines [12].",
            "startOffset": 18370,
            "title": "Replication-incompetent viral vaccines"
        },
        {
            "endOffset": 20345,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "refoffsets": {
                "b0085": {
                    "endOffset": 20219,
                    "startOffset": 20212
                },
                "b0090": {
                    "endOffset": 20219,
                    "startOffset": 20212
                }
            },
            "secId": "s0025",
            "sentence": "rVSV-ZEBOV is the only vaccine whose efficacy in preventing Ebola virus disease has been evaluated in clinical trials [17,18], and it is currently used in the Republic of the Congo as a compassionate-use program for outbreaks of Ebola virus (Table 2).",
            "startOffset": 20094,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 34369,
            "parents": [],
            "secId": "s0125",
            "sentence": "A recombinant virus should therefore not be shed from vaccinated individuals; alternatively, recombinant viruses that are shed should be under control.",
            "startOffset": 34218,
            "title": "Conclusion"
        },
        {
            "endOffset": 22042,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0035",
            "sentence": "The characterization of recombinant viruses is improved by knowledge of the characteristics of the original virus.",
            "startOffset": 21928,
            "title": "Original viruses used to generate recombinant viruses"
        },
        {
            "endOffset": 21527,
            "parents": [],
            "secId": "s0030",
            "sentence": "The results of these evaluations are expected to reveal potential risks associated with recombinant viral vaccines, and these risks should be considered in the design of non-clinical/clinical studies.",
            "startOffset": 21327,
            "title": "Quality aspects of recombinant viral vaccines and their characterization"
        },
        {
            "endOffset": 17714,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0020",
            "sentence": "Replication-incompetent viral vaccines are constructed from viral vectors which lack essential gene(s) related to viral replication.",
            "startOffset": 17582,
            "title": "Replication-incompetent viral vaccines"
        },
        {
            "endOffset": 32710,
            "parents": [],
            "secId": "s0125",
            "sentence": "The safety and the efficacy of recombinant viral vaccines are thus poorly understood.",
            "startOffset": 32625,
            "title": "Conclusion"
        },
        {
            "endOffset": 27051,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0075",
            "sentence": "Although genotoxicity and carcinogenicity studies are generally not required for vaccines, if there is a concern about the characteristics of the original virus or the recombinant virus, an evaluation of the concerns should be performed via genotoxicity and carcinogenicity studies using a feasible and appropriate approach.",
            "startOffset": 26727,
            "title": "Genotoxicity and carcinogenicity studies"
        },
        {
            "endOffset": 31128,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0105",
            "sentence": "The relationship between tissue distribution and tissue/organ-specific adverse events (when the recombinant virus is found to localize in certain tissues/organs in a biodistribution study).",
            "startOffset": 30939,
            "title": "Principles of safety evaluations"
        },
        {
            "endOffset": 29860,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0095",
            "sentence": "If persistent shedding of a replication-competent recombinant viral vaccine is observed, continuous testing will be required to rule out infection due to close contact with recipients.",
            "startOffset": 29676,
            "title": "Principles of the evaluation of shedding and transmission to third parties"
        },
        {
            "endOffset": 18259,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0020",
            "sentence": "The vaccines can transfect cells and express the target antigen protein in vivo, and they may therefore be expected to induce not only humoral immunity but also cellular immunity.",
            "startOffset": 18080,
            "title": "Replication-incompetent viral vaccines"
        },
        {
            "endOffset": 30558,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0105",
            "sentence": "The safety of recombinant viral vaccines should be determined with a focus on the following risk factors, which should be carefully investigated in early clinical studies.",
            "startOffset": 30387,
            "title": "Principles of safety evaluations"
        },
        {
            "endOffset": 13612,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 13611,
                    "startOffset": 13606
                },
                "b0030": {
                    "endOffset": 13611,
                    "startOffset": 13606
                }
            },
            "secId": "s0005",
            "sentence": "Although recombinant viral vaccines are expected to have higher efficacy than conventional vaccines, the safety and efficacy of recombinant viral vaccines in medical use are not yet established [5,6].",
            "startOffset": 13412,
            "title": "Introduction"
        },
        {
            "endOffset": 17841,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0020",
            "sentence": "In general, transformed cell lines expressing the essential gene(s) are used to produce replication-incompetent viral vaccine.",
            "startOffset": 17715,
            "title": "Replication-incompetent viral vaccines"
        },
        {
            "endOffset": 20965,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0025",
            "sentence": "The use of these vaccines is limited to regions under the threat of highly pathogenic viruses.",
            "startOffset": 20871,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 22500,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0040",
            "sentence": "Additional studies may be required depending on the characteristics of the recombinant virus.",
            "startOffset": 22407,
            "title": "Characterization of recombinant viruses"
        },
        {
            "endOffset": 18079,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0020",
            "sentence": "The replication-incompetent viral vaccines can deliver a specific recombinant gene to cells in vivo and express foreign proteins such as the antigen of pathogens, but the vaccines are unable to replicate themselves in the infected cells.",
            "startOffset": 17842,
            "title": "Replication-incompetent viral vaccines"
        },
        {
            "endOffset": 22731,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0040",
            "sentence": "Determination of the level, efficiency, and persistence of antigen expression in infected cells.",
            "startOffset": 22635,
            "title": "Characterization of recombinant viruses"
        },
        {
            "endOffset": 21326,
            "parents": [],
            "secId": "s0030",
            "sentence": "RVVRG\u2019s concept paper requires that quality evaluations of each recombinant viral vaccine include the following three points; (1) the nature of the original virus used to generate the recombinant virus, (2) the characterization of the recombinant virus, and (3) the manufacturing process.",
            "startOffset": 21038,
            "title": "Quality aspects of recombinant viral vaccines and their characterization"
        },
        {
            "endOffset": 21927,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0035",
            "sentence": "The characteristics of the original viruses used for the construction of recombinant viruses provide important information for the evaluation of the recombinant viruses\u2019 characteristics as mentioned in Section 4.2.",
            "startOffset": 21713,
            "title": "Original viruses used to generate recombinant viruses"
        },
        {
            "endOffset": 23661,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0045",
            "sentence": "The genetic heterogeneity of the recombinant virus in the drug product should be determined, as it serves as a measure for ensuring the consistency of the manufacturing process.",
            "startOffset": 23484,
            "title": "Evaluation during the manufacturing process"
        },
        {
            "endOffset": 26018,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "In addition, since an investigation of persistence (including the distribution and elimination) of a recombinant virus yields information that is useful in the determination of the appropriate duration of clinical studies in humans, the obtained biodistribution information should be reflected in the clinical study design.",
            "startOffset": 25695,
            "title": "Biodistribution study"
        },
        {
            "endOffset": 33207,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 33206,
                    "startOffset": 33196
                },
                "b0085": {
                    "endOffset": 33206,
                    "startOffset": 33196
                },
                "b0100": {
                    "endOffset": 33206,
                    "startOffset": 33196
                }
            },
            "secId": "s0125",
            "sentence": "However, recombinant viral vaccines are expected to induce a stronger immune response than that induced by conventional vaccines, and several recombinant replication-competent and -incompetent viral vaccines have been confirmed to confer protection against target-infectious diseases: rVSV-ZEBOV, Dengvaxia\u00ae, and canarypox-based HIV-1 [15,17,20].",
            "startOffset": 32861,
            "title": "Conclusion"
        },
        {
            "endOffset": 15874,
            "parents": [],
            "secId": "s0010",
            "sentence": "And besides, the concept paper aimed to provide considerations about quality, non-clinical, and clinical evaluations that are specific to the development of recombinant viral vaccines.",
            "startOffset": 15690,
            "title": "Objectives and scope"
        },
        {
            "endOffset": 15004,
            "parents": [],
            "secId": "s0005",
            "sentence": "In Japan, there has been neither authorized guidelines nor points-to-consider to address recombinant viral vaccines like the EMA guideline.",
            "startOffset": 14865,
            "title": "Introduction"
        },
        {
            "endOffset": 11968,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 11967,
                    "startOffset": 11964
                }
            },
            "secId": "s0005",
            "sentence": "The recent progress in genetic recombination techniques and biotechnology has accelerated the development of new types of prophylactic vaccines for infectious diseases for which conventional vaccines are not available or are insufficiently effective [1].",
            "startOffset": 11714,
            "title": "Introduction"
        },
        {
            "endOffset": 29419,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0095",
            "sentence": "In a phase I trial, the amount of the recombinant virus at the injection site and in blood, and body fluids where viral shedding is expected should be measured over time using evaluable samples to accurately determine the persistence of the recombinant virus in the human body and the duration of viral shedding.",
            "startOffset": 29107,
            "title": "Principles of the evaluation of shedding and transmission to third parties"
        },
        {
            "endOffset": 13820,
            "parents": [],
            "secId": "s0005",
            "sentence": "For example, compared to conventional vaccines the recombinant viral vaccines may have a considerably different safety profile in individuals such as newborns, pregnant women, and immunocompromised patients.",
            "startOffset": 13613,
            "title": "Introduction"
        },
        {
            "endOffset": 22871,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0040",
            "sentence": "Evaluation of the risk of integration into chromosomes.",
            "startOffset": 22816,
            "title": "Characterization of recombinant viruses"
        },
        {
            "endOffset": 34665,
            "parents": [],
            "secId": "s0125",
            "sentence": "The risk-benefit balance of each new recombinant viral vaccine must also be determined.",
            "startOffset": 34578,
            "title": "Conclusion"
        },
        {
            "endOffset": 13275,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 13274,
                    "startOffset": 13271
                }
            },
            "secId": "s0005",
            "sentence": "Recombinant viral vaccines targeting pathogens that constitute a great public health threat against which no approved effective vaccines are available (e.g., Ebola virus and HIV) are now being developed [2].",
            "startOffset": 13068,
            "title": "Introduction"
        },
        {
            "endOffset": 32860,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 32859,
                    "startOffset": 32849
                },
                "b0075": {
                    "endOffset": 32859,
                    "startOffset": 32849
                },
                "b0085": {
                    "endOffset": 32859,
                    "startOffset": 32849
                }
            },
            "secId": "s0125",
            "sentence": "A small number of recombinant viral vaccines are licensed only in the limited areas under the threat of high pathogenic viruses (Table.2) [14,15,17].",
            "startOffset": 32711,
            "title": "Conclusion"
        },
        {
            "endOffset": 16024,
            "parents": [],
            "secId": "s0010",
            "sentence": "The scope of the concept paper covers live recombinant viral vaccines intended for infectious diseases that are generated using genetic recombination.",
            "startOffset": 15874,
            "title": "Objectives and scope"
        },
        {
            "endOffset": 27368,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 27367,
                    "startOffset": 27360
                },
                "b0100": {
                    "endOffset": 27367,
                    "startOffset": 27360
                }
            },
            "secId": "s0080",
            "sentence": "An immunogenicity study should assess not only the immune response specific to the antigen(s) but also the response specific to other viral proteins contained in the recombinant virus, because pre-existing immunity against the viral vectors may hamper a vaccine\u2019s clinical use [12,20].",
            "startOffset": 27083,
            "title": "Evaluations of immunogenicity"
        },
        {
            "endOffset": 15253,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 15252,
                    "startOffset": 15249
                }
            },
            "secId": "s0005",
            "sentence": "In 2018, the research group for quality and safety issued on recombinant viral vaccines (RVVRG) organized under the auspices of the Ministry of Health, Labour and Welfare, Japan (MHLW) published a concept paper about recombinant viral vaccines [9].",
            "startOffset": 15005,
            "title": "Introduction"
        },
        {
            "endOffset": 30774,
            "parents": [
                {
                    "id": "s0090",
                    "title": "Viral shedding study and transmission to third parties"
                }
            ],
            "secId": "s0105",
            "sentence": "The potential for an unexpected replication of the recombinant virus in the recipient\u2019s body (for replication-incompetent recombinant viral vaccines).",
            "startOffset": 30624,
            "title": "Principles of safety evaluations"
        },
        {
            "endOffset": 20569,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 20568,
                    "startOffset": 20564
                }
            },
            "secId": "s0025",
            "sentence": "Since poxviruses have large genomes that potentially accept many foreign genes, the vaccinia virus, which belongs to the poxvirus family, is frequently used as the major viral vector for the expression of foreign genes [19].",
            "startOffset": 20345,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 22290,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0035",
            "sentence": "In principle, viruses that have a potential to integrate gene(s) into the recipients\u2019 chromosome should not be used as the original virus, because recombinant viral vaccines are generally used for the prevention of infection in healthy individuals.",
            "startOffset": 22042,
            "title": "Original viruses used to generate recombinant viruses"
        },
        {
            "endOffset": 26684,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 26656,
                    "startOffset": 26652
                }
            },
            "secId": "s0070",
            "sentence": "Shedding of a recombinant virus can be evaluated in a biodistribution study or other toxicity studies, referring to \u201cICH Considerations: General Principles to Address Virus and Vector Shedding\u201d [22] for an evaluation approach.",
            "startOffset": 26458,
            "title": "Evaluations of the shedding of a recombinant virus"
        },
        {
            "endOffset": 24890,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0055",
            "sentence": "Areas of non-compliance should be identified and their significance should be evaluated relative to the overall toxicity assessment.",
            "startOffset": 24758,
            "title": "Selection of animal species/models"
        },
        {
            "endOffset": 32409,
            "parents": [
                {
                    "id": "s0110",
                    "title": "Efficacy of recombinant viral vaccines"
                }
            ],
            "secId": "s0120",
            "sentence": "If the recombinant viral vaccine is based on an approved live attenuated vaccine, the two vaccines\u2019 mutual interference in immunogenicity should be evaluated by clinical studies that take into consideration the vaccination schedule used for the approved live vaccine in clinical use.",
            "startOffset": 32126,
            "title": "Principles of immunogenicity evaluations"
        },
        {
            "endOffset": 25694,
            "parents": [
                {
                    "id": "s0050",
                    "title": "Non-clinical studies of recombinant viral vaccines"
                }
            ],
            "secId": "s0060",
            "sentence": "If a concern arises in a biodistribution study, additional non-clinical studies should therefore be considered.",
            "startOffset": 25583,
            "title": "Biodistribution study"
        },
        {
            "endOffset": 33650,
            "parents": [],
            "secId": "s0125",
            "sentence": "RVVRG\u2019s concept paper is similar to the 2009 EMA guideline, but the concept paper focuses on the safety of not only vaccine recipients but also those of the people in close contact with the recipients.",
            "startOffset": 33449,
            "title": "Conclusion"
        },
        {
            "endOffset": 17541,
            "parents": [],
            "secId": "s0015",
            "sentence": "Since recombinant viral vaccines have many variations that depend on their characteristics and replication abilities, the vaccines should be evaluated on a case-by-case basis in order to evaluate their CMC (chemistry, manufacturing and control) and safety.",
            "startOffset": 17285,
            "title": "Current status of recombinant viral vaccines"
        },
        {
            "endOffset": 20093,
            "parents": [
                {
                    "id": "s0015",
                    "title": "Current status of recombinant viral vaccines"
                }
            ],
            "secId": "s0025",
            "sentence": "rVSV-ZEBOV is a recombinant VSV vaccine containing the gene of a glycoprotein of Zaire strain Ebola virus instead of the gene of G protein of VSV.",
            "startOffset": 19947,
            "title": "Replication-competent viral vaccines"
        },
        {
            "endOffset": 33945,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 33944,
                    "startOffset": 33940
                }
            },
            "secId": "s0125",
            "sentence": "The reason for this focus is that an unexpected infection with a recombinant virus in persons in close contact with a vaccine recipient can occur because vaccines are usually administered to numerous healthy individuals, as has been observed with the use of live attenuated polio vaccines [23].",
            "startOffset": 33651,
            "title": "Conclusion"
        },
        {
            "endOffset": 12292,
            "parents": [],
            "secId": "s0005",
            "sentence": "Vaccines that deliver the gene(s) coding different species antigen(s), such as viral vectors for gene therapy, are also being developed.",
            "startOffset": 12156,
            "title": "Introduction"
        },
        {
            "endOffset": 31744,
            "parents": [
                {
                    "id": "s0110",
                    "title": "Efficacy of recombinant viral vaccines"
                }
            ],
            "secId": "s0115",
            "sentence": "Efficacy evaluations also serve to identify the potential risks of the adverse events associated with recombinant viral vaccines not only in recipients but also in third parties.",
            "startOffset": 31566,
            "title": "Principles of efficacy evaluations"
        },
        {
            "endOffset": 28435,
            "parents": [],
            "secId": "s0090",
            "sentence": "RVVRG\u2019s concept paper addresses more details of the evaluation of viral shedding and the potential transmission, referring to the 2009 EMA guideline.",
            "startOffset": 28286,
            "title": "Viral shedding study and transmission to third parties"
        },
        {
            "endOffset": 22634,
            "parents": [
                {
                    "id": "s0030",
                    "title": "Quality aspects of recombinant viral vaccines and their characterization"
                }
            ],
            "secId": "s0040",
            "sentence": "Determination of species-specificity, cellular/tissue tropism, replication characteristics, and cytotoxicity.",
            "startOffset": 22525,
            "title": "Characterization of recombinant viruses"
        }
    ],
    "docId": "S0264410X19310953",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "sakurai-akira@pmda.go.jp",
                "first": "Akira",
                "initial": "A.",
                "last": "Sakurai"
            },
            {
                "email": "ogawa-takashi@pmda.go.jp",
                "first": "Takashi",
                "initial": "T.",
                "last": "Ogawa"
            },
            {
                "email": "matsumoto-jun@pmda.go.jp",
                "first": "Jun",
                "initial": "J.",
                "last": "Matsumoto"
            },
            {
                "email": "kihira-tetsunari@pmda.go.jp",
                "first": "Tetsunari",
                "initial": "T.",
                "last": "Kihira"
            },
            {
                "email": "fuku789@tokyo-med.ac.jp",
                "first": "Shinji",
                "initial": "S.",
                "last": "Fukushima"
            },
            {
                "email": "miyata.kkcl@gmail.com",
                "first": "Ippei",
                "initial": "I.",
                "last": "Miyata"
            },
            {
                "email": "shimizu-h@city.kawasaki.jp",
                "first": "Hideaki",
                "initial": "H.",
                "last": "Shimizu"
            },
            {
                "email": "sitamura@nih.go.jp",
                "first": "Shigeyuki",
                "initial": "S.",
                "last": "Itamura"
            },
            {
                "email": "kouchi@med.kawasaki-m.ac.jp",
                "first": "Kazunobu",
                "initial": "K.",
                "last": "Ouchi"
            },
            {
                "email": "a-hamada@tokyo-med.ac.jp",
                "first": "Atsuro",
                "initial": "A.",
                "last": "Hamada"
            },
            {
                "email": "k-tani@ims.u-tokyo.ac.jp",
                "first": "Kenzaburo",
                "initial": "K.",
                "last": "Tani"
            },
            {
                "email": "okaben-n@city.kawasaki.jp",
                "first": "Nobuhiko",
                "initial": "N.",
                "last": "Okabe"
            },
            {
                "email": "t-yamaguchi@nichiyaku.ac.jp",
                "first": "Teruhide",
                "initial": "T.",
                "last": "Yamaguchi"
            }
        ],
        "doi": "10.1016/j.vaccine.2019.08.031",
        "firstpage": "6573",
        "issn": "0264410X",
        "lastpage": "6579",
        "openaccess": "Full",
        "pub_year": 2019,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Regulatory aspects of quality and safety for live recombinant viral vaccines against infectious diseases in Japan"
    }
}